Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Cross-neutralization of SARS and COVID-19 coronaviruses by an antibody

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the cause of COVID-19.

19 May 2020

Study shows coronavirus does not induce cross-protective immune antibodies

According to researchers, patients infected with severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 generate antibodies that adhere to the other coronavirus; however, the cross-reactive antibodies are not actually cross-protective, as far as cell-culture experiments are concerned.

19 May 2020

Discovery Of Antibody That Blocks Infection Of SARS-Cov-2

Researchers reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells.

4 May 2020

Beta Cells From Stem Cells

The loss of insulin-secreting beta cells leads to type 1 diabetes. Islet cell transplantation has the potential to cure diabetes, but donors are rare.

28 Apr 2020

Discovery marks a critical step toward developing new anti-cancer drugs

A team of scientists led by the University of Michigan Rogel Cancer Center and Case Comprehensive Cancer Center has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.

21 Apr 2020

IL-2's flexible structure helping the immune system

Scientists have known that interleukin-2 (IL-2), a signaling molecule, strongly influences the immune system. However, attempts to leverage its potential for therapeutic purposes have went futile due to serious side effects.

From University of California Santa Cruz 18 Mar 2020